GRIK2 Gene

📖 Wiki Page

gene1776 wordssynced 2026-04-02

GRIK2 Gene

Introduction

<table class="infobox infobox-gene">
<tr>
<th class="infobox-header" colspan="2">GRIK2 Gene</th>
</tr>
<tr>
<td class="label">Gene Symbol</td>
<td>GRIK2</td>
</tr>
<tr>
<td class="label">Full Name</td>
<td>Glutamate Ionotropic Receptor Kainate Type Subunit 2</td>
</tr>
<tr>
<td class="label">Chromosomal Location</td>
<td>6q16.3</td>
</tr>
<tr>
<td class="label">NCBI Gene ID</td>
<td>2899</td>
</tr>
<tr>
<td class="label">OMIM ID</td>
<td>138244</td>
</tr>
<tr>
<td class="label">Ensembl ID</td>
<td>ENSG00000164418</td>
</tr>
<tr>
<td class="label">UniProt ID</td>
<td>Q16478</td>
</tr>
<tr>
<td class="label">Protein Name</td>
<td>Glutamate receptor 6 (GluK2)</td>
</tr>
<tr>
<td class="label">Protein Class</td>
<td>Ionotropic glutamate receptor (kainate type)</td>
</tr>
<tr>
<td class="label">Brain Region</td>
<td>Expression Level</td>
</tr>
<tr>
<td class="label">[Hippocampus](/brain-regions/hippocampus)</td>
<td>High</td>
</tr>
<tr>
<td class="label">Cerebral [cortex](/brain-regions/cortex)</td>
<td>High</td>
</tr>
<tr>
<td class="label">[Amygdala](/brain-regions/amygdala)</td>
<td>High</td>
</tr>
<tr>
<td class="label">[Cerebellum](/brain-regions/cerebellum)</td>
<td>Moderate</td>
</tr>
<tr>
<td class="label">[Striatum](/brain-regions/striatum)</td>
<td>Moderate</td>
</tr>
<tr>
<td class="label">[Thalamus](/brain-regio

...

GRIK2 Gene

Introduction

The GRIK2 gene (formerly known as GLUR6 or GluK2) encodes the GluK2 subunit of the kainate family of ionotropic glutamate receptors. Kainate receptors represent a distinct class of glutamate-gated ion channels that play critical roles in synaptic transmission, neuronal excitability, and synaptic plasticity throughout the central nervous system. Unlike AMPA and NMDA receptors, kainate receptors exhibit unique pharmacological properties, slow kinetics, and are expressed both pre- and post-synaptically where they modulate neurotransmitter release and cellular signaling pathways[@carpenter2023][@contractor2022].

The GRIK2 gene is located on chromosome 6q16.3 and encodes a protein of approximately 906 amino acids. The GluK2 subunit can form homomeric channels or heteromeric channels when co-assembled with other kainate receptor subunits (GluK1, GluK3, GluK4, or GluK5), creating a diverse repertoire of receptor configurations with distinct pharmacological and physiological properties. Mutations in GRIK2 have been implicated in neurodevelopmental disorders including autism spectrum disorder (ASD) and intellectual disability, while altered GRIK2 expression and function are observed in Alzheimer's disease, Parkinson's disease, and amyotrophic lateral sclerosis (ALS)[@fernandez2023][@gomez2024].

Gene Overview

Protein Structure and Function

Molecular Architecture

Like other ionotropic glutamate receptors, GluK2 adopts a modular structure comprising four distinct domains that transduce ligand binding into ion channel opening:

Extracellular N-terminal domain (NTD): Controls receptor assembly, trafficking, and contributes to allosteric modulation; contains the kainate-binding domain

Ligand-binding domain (LBD): Binds glutamate and selective agonists (kainic acid, ATPA); undergoes closure upon agonist binding that drives channel opening

Transmembrane domain (TMD): Forms the ion channel pore, with four transmembrane helices (M1-M4); the channel gate is located at M3

C-terminal intracellular domain (CTD): Contains sites for phosphorylation, ubiquitination, and protein-protein interactions that regulate trafficking and signaling

The subunit composition of kainate receptors dramatically influences their properties. GRIK2 can form functional homomeric receptors (GluK2/GluK2) and heteromeric receptors with other subunits, creating receptors with distinct single-channel conductances, pharmacology, and trafficking characteristics[@huettner2023][@upton2023].

RNA Editing

GRIK2 undergoes RNA editing at multiple sites, analogous to AMPA receptor subunits:

Q/R site editing (site 1): Located in the M2 pore helix, converting glutamine to arginine
I/V site editing (site 2): Located in the M1 helix
Y/C site editing (site 3): Located in the extracellular domain

These editing events alter the biophysical properties of kainate receptors, including single-channel conductance, calcium permeability, and desensitization kinetics. The Q/R site editing in particular reduces calcium permeability, similar to its effect in AMPA receptors[@borgesius2021][@noguchi2023].

Role in Synaptic Transmission

Presynaptic Modulation

Kainate receptors, including those containing GluK2 subunits, are prominently located on presynaptic terminals where they regulate neurotransmitter release[@jiang2022]:

Autoreceptor function: Presynaptic GluK2 receptors sense glutamate released from the same terminal, providing feedback regulation of release probability
Presynaptic plasticity: Activation of presynaptic kainate receptors can produce both short-term and long-term modifications of neurotransmitter release
Modulation of GABA release: Presynaptic GluK2 receptors on inhibitory terminals modulate GABA release, influencing network excitability

The presynaptic location of kainate receptors makes them uniquely positioned to regulate circuit function through modulation of both excitatory and inhibitory transmission.

Postsynaptic Signaling

Postsynaptic kainate receptors mediate slow excitatory postsynaptic potentials (EPSPs) and contribute to synaptic integration:

Slow kinetic responses: Kainate receptor activation produces currents with slow rise and decay times, contributing to temporal integration
Interaction with NMDA receptors: Kainate receptor activation can potentiate NMDA receptor responses in some contexts
Dendritic integration: Kainate receptors on dendritic shafts and spines contribute to synaptic integration and plasticity

Synaptic Plasticity

Kainate receptors are intimately involved in various forms of synaptic plasticity[@kumar2023][@lerma2022]:

LTP induction: GluK2-containing receptors contribute to induction of long-term potentiation in some brain regions
LTD induction: Activation of specific kainate receptor subtypes can trigger long-term depression
Metaplasticity: Kainate receptors regulate the threshold for plasticity induction through their modulatory effects on network excitability

Disease Associations

Autism Spectrum Disorder and Intellectual Disability

GRIK2 is one of the most consistently implicated glutamate receptor genes in neurodevelopmental disorders[@fernandez2023]:

De novo variants: Rare de novo missense variants in GRIK2 cause intellectual disability with or without ASD
Loss-of-function variants: Truncating mutations and deletion of GRIK2 are associated with severe developmental delay
Mutational burden: Increased burden of rare coding variants in GRIK2 has been observed in ASD cohorts

The mechanism likely involves disruption of kainate receptor function during critical periods of brain development, affecting circuit formation and refinement.

Alzheimer's Disease

Alzheimer's disease is associated with multiple alterations in GRIK2 expression and function that contribute to synaptic dysfunction[@gomez2024][@mendez2024]:

Expression changes: Studies of AD brain tissue reveal altered GRIK2 expression in affected regions, including the hippocampus and cortex. The direction and magnitude of changes vary by brain region and disease stage.

Synaptic dysfunction: Kainate receptors are sensitive targets of amyloid-beta (Aβ) oligomer toxicity:

Aβ oligomers disrupt GluK2 trafficking to synapses
Altered kainate receptor function contributes to synaptic hyperexcitability
Dysregulated GluK2 signaling may exacerbate excitatory/inhibitory imbalance

Therapeutic implications: Kainate receptor modulators represent a potential therapeutic approach for AD, though subunit selectivity is critical to avoid unwanted side effects.

Parkinson's Disease and Dyskinesias

Kainate receptors play a complex role in Parkinson's disease and L-DOPA-induced dyskinesias (LID)[@taylor2023]:

Basal ganglia expression: High levels of GluK2 expression in the striatum and subthalamic nucleus
Dyskinesia development: Kainate receptor activation contributes to the abnormal synaptic plasticity underlying LID
Therapeutic targeting: Kainate receptor antagonists reduce LID in animal models, suggesting therapeutic potential

Amyotrophic Lateral SALS

Emerging evidence links GRIK2 dysfunction to ALS pathogenesis[@zhang2024][@paoletti2023]:

RNA editing alterations: Reduced editing of GRIK2 Q/R site in ALS motor cortex
Excitotoxicity: Enhanced calcium permeability through unedited GluK2 receptors may contribute to motor neuron vulnerability
Expression changes: Altered GRIK2 expression in ALS spinal cord and motor cortex

Epilepsy

Kainate receptors have historically been associated with epilepsy research since kainic acid itself is a potent seizure-inducing agent[@ortiz2022]:

Seizure initiation: GluK2-containing receptors mediate the convulsive effects of kainic acid
Temporal lobe epilepsy: Altered GRIK2 expression and editing in epileptic tissue
Therapeutic targeting: Antagonists of GluK2-containing receptors have anti-epileptic potential

Expression Pattern

Regional Distribution

GRIK2 shows a characteristic pattern of expression throughout the brain:

The high hippocampal expression suggests important roles in learning and memory, while cortical and striatal expression implicates GRIK2 in higher-order cognitive and motor functions.

Cellular Localization

Neurons: Expressed in both excitatory glutamatergic and inhibitory GABAergic neurons
Astrocytes: Low expression; primarily neuronal
Synaptic terminals: Present at both pre- and postsynaptic locations

Therapeutic Targets

Kainate Receptor Agonists and Antagonists

Selective pharmacological tools for kainate receptors have been developed[@qian2024][@yang2022]:

GluK1 agonists: ATPA (amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid) - GluK1 selective
GluK2/3 antagonists: LY466365, LY382884 - reduce excitotoxicity
Broad-spectrum antagonists: Kynurenic acid derivatives

The challenge has been achieving sufficient subunit selectivity while crossing the blood-brain barrier.

Positive Allosteric Modulators

Unlike AMPAkines, less development has occurred for kainate receptor positive modulators, though some compounds have been identified that enhance kainate receptor function.

Gene Therapy Approaches

Viral vector-mediated delivery of GRIK2 or modulators of GRIK2 function represents a potential therapeutic strategy for conditions with GRIK2 dysfunction.

Animal Models

Knockout Mice

Grik2 knockout mice exhibit:

Reduced seizure threshold
Impaired synaptic plasticity in the hippocampus
Behavioral alterations including anxiety-related phenotypes
Developmental abnormalities in some studies

Transgenic and Knock-in Models

Various genetic models have been developed to study:

Cell-type-specific GRIK2 function
Disease-associated mutations
RNA editing requirements

Research Directions

Current Areas of Investigation

Subunit-selective pharmacology: Developing compounds with improved selectivity for GluK2-containing receptors

RNA editing therapeutics: Enhancing GRIK2 editing as a treatment strategy

Circuit-level mechanisms: Understanding how GluK2 dysfunction affects neural circuits

Disease mechanisms: Elucidating the specific contributions of GRIK2 to various disorders

Emerging Technologies

Single-cell RNAseq: Cell-type-specific understanding of GRIK2 expression
Optogenetic tools: Light-activated kainate receptors for precise circuit manipulation
CRISPR screening: Identifying genetic modifiers of GRIK2 function

Summary

The GRIK2 gene encodes the GluK2 kainate receptor subunit, a critical component of excitatory synaptic transmission in the brain. Through its roles in presynaptic modulation, postsynaptic signaling, and synaptic plasticity, GluK2 influences fundamental aspects of neural circuit function. GRIK2 dysfunction is implicated in neurodevelopmental disorders (ASD, intellectual disability), neurodegenerative diseases (AD, PD, ALS), and epilepsy. Understanding the molecular mechanisms by which GRIK2 contributes to these conditions, and developing targeted therapeutic interventions, represents an important frontier in neuroscience research.

References

[Borgesius et al., RNA editing of glutamate receptors (2021)](https://pubmed.ncbi.nlm.nih.gov/33823754/)

[Carpenter et al., Kainate receptor physiology (2023)](https://pubmed.ncbi.nlm.nih.gov/37217612/)

[Contractor et al., Kainate receptors: From function to disease (2022)](https://pubmed.ncbi.nlm.nih.gov/35644532/)

[Fernandez et al., GRIK2 variants in neurodevelopmental disorders (2023)](https://pubmed.ncbi.nlm.nih.gov/36927789/)

[Gomez et al., Kainate receptors in AD (2024)](https://pubmed.ncbi.nlm.nih.gov/38574019/)

[Huettner et al., Kainate receptor subunit structure (2023)](https://pubmed.ncbi.nlm.nih.gov/37429563/)

[Jiang et al., Presynaptic kainate receptors (2022)](https://pubmed.ncbi.nlm.nih.gov/35678654/)

[Kumar et al., Kainate receptors in synaptic plasticity (2023)](https://pubmed.ncbi.nlm.nih.gov/37054921/)

[Lerma et al., Kainate receptor desensitization (2022)](https://pubmed.ncbi.nlm.nih.gov/35271891/)

[Mendez et al., Glutamate receptor trafficking in neurodegeneration (2024)](https://pubmed.ncbi.nlm.nih.gov/38327189/)

[Noguchi et al., RNA editing of kainate receptors (2023)](https://pubmed.ncbi.nlm.nih.gov/37642178/)

[Ortiz et al., Kainate receptors in epilepsy (2022)](https://pubmed.ncbi.nlm.nih.gov/35190823/)

[Paoletti et al., Kainate receptor signaling in neuroprotection (2023)](https://pubmed.ncbi.nlm.nih.gov/37294632/)

[Qian et al., Kainate receptors as therapeutic targets (2024)](https://pubmed.ncbi.nlm.nih.gov/38492756/)

[Rodriguez et al., Kainate receptor-associated proteins (2023)](https://pubmed.ncbi.nlm.nih.gov/37564789/)

[Song et al., Alternative splicing of kainate receptors (2022)](https://pubmed.ncbi.nlm.nih.gov/35428519/)

[Taylor et al., Kainate receptors in PD and dyskinesias (2023)](https://pubmed.ncbi.nlm.nih.gov/37253921/)

[Upton et al., Dissecting kainate receptor composition (2023)](https://pubmed.ncbi.nlm.nih.gov/37620569/)

[Wang et al., Kainate receptors on GABAergic interneurons (2024)](https://pubmed.ncbi.nlm.nih.gov/38383927/)

[Yang et al., Targeting kainate receptors for pain (2022)](https://pubmed.ncbi.nlm.nih.gov/35246328/)

[Zhang et al., Kainate receptors in ALS (2024)](https://pubmed.ncbi.nlm.nih.gov/38657834/)

External Links

[NCBI Gene: GRIK2](https://www.ncbi.nlm.nih.gov/gene/2899)
[UniProt: Q16478](https://www.uniprot.org/uniprot/Q16478)
[OMIM: 138244](https://www.omim.org/entry/138244)
[Ensembl: GRIK2](https://www.ensembl.org/Homo_sapiens/ENSG00000164418)
[Allen Brain Atlas: GRIK2 Expression](https://human.brain-map.org/microarray/search/show?search_term=GRIK2)

📖 View canonical wiki page →

GRIK2 Gene

GRIK2 Gene

Introduction

GRIK2 Gene

Introduction

Gene Overview

Protein Structure and Function

Molecular Architecture

RNA Editing

Role in Synaptic Transmission

Presynaptic Modulation

Postsynaptic Signaling

Synaptic Plasticity

Disease Associations

Autism Spectrum Disorder and Intellectual Disability

Alzheimer's Disease

Parkinson's Disease and Dyskinesias

Amyotrophic Lateral SALS

Epilepsy

Expression Pattern

Regional Distribution

Cellular Localization

Therapeutic Targets

Kainate Receptor Agonists and Antagonists

Positive Allosteric Modulators

Gene Therapy Approaches

Animal Models

Knockout Mice

Transgenic and Knock-in Models

Research Directions

Current Areas of Investigation

Emerging Technologies

Summary

See Also

References

External Links